Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume 110, Issue 12, Pages 1809-1813Publisher
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2012.08.015
Keywords
-
Categories
Funding
- National Institutes of Health, Bethesda, Maryland [R37AG18915, P30AG21332]
- Novartis Pharmaceuticals, East Hanover, New Jersey
- Novartis
- Boston Scientific Corp.
Ask authors/readers for more resources
Exercise intolerance is the primary symptom in patients with heart failure and preserved ejection fraction (HFpEF), a major determinant of their decreased quality of life, and an important outcome in clinical trials. Although cardiopulmonary exercise testing (CPET) provides peak and submaximal diagnostic indexes, the reliability of peak treadmill CPET in patients >55 years of age with HFpEF has not been examined. Two CPETs were performed in 52 patients with HFpEF (70 +/- 7 years old). The 2 tests were separated by an average of 23 +/- 13 days (median 22) and performed under identical conditions, with no intervention or change in status between visits except for initiation of a placebo run-in. A multistep protocol for patient screening, education, and quality control was used. Mean peak oxygen consumption was similar on tests 1 and 2 (14.4 +/- 2.4 vs 14.3 +/- 2.3 ml/kg/min). Correlation coefficients and intraclass correlations from the testing days were determined (oxygen consumption, r = 0.85, p <0.001, intraclass correlation 0.855; ventilatory anaerobic threshold, r = 0.79, p <0.001, intraclass correlation 0.790; ventilation per carbon dioxide slope, r = 0.87, p <0.001, intraclass correlation 0.864; heart rate, r = 0.94, p <0.001, intraclass correlation 0.938). These results challenge conventional wisdom that serial baseline testing is required in clinical trials with exercise-capacity outcomes. In conclusion, in women and men with HFpEF and severe physical dysfunction, key submaximal and peak ET variables exhibited good reliability and were not significantly altered by a learning effect or placebo administration. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:1809-1813)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available